Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rocket Pharmaceuticals ( (RCKT) ) just unveiled an announcement.
On March 10, 2026, Rocket Pharmaceuticals, Inc. entered into a new at-the-market equity offering program with Cantor Fitzgerald & Co., allowing the company to sell up to $100 million of its common stock from time to time under a previously filed shelf registration. The arrangement gives Rocket flexibility to control the timing, size, pricing, and method of stock sales on Nasdaq or other markets, with Cantor acting on a commercially reasonable efforts basis and receiving up to a 3% commission plus expense reimbursement.
The company simultaneously terminated its prior at-the-market sales agreement with Cowen and Company, LLC, which had been in place since February 28, 2022 and amended on September 12, 2023. The shift to a new sales agent marks an adjustment in Rocket’s capital-raising strategy, potentially affecting its funding costs and access to equity markets while maintaining an established mechanism for incremental share issuance.
The most recent analyst rating on (RCKT) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Rocket Pharmaceuticals stock, see the RCKT Stock Forecast page.
Spark’s Take on RCKT Stock
According to Spark, TipRanks’ AI Analyst, RCKT is a Neutral.
The score is held back primarily by weak financial performance (no revenue, persistent losses, and ongoing cash burn with equity erosion risk). Technicals are supportive due to strong trend and positive MACD, but extremely overbought RSI/Stochastics temper the technical score. Valuation is constrained by negative earnings and no provided dividend yield.
To see Spark’s full report on RCKT stock, click here.
More about Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc. is a biopharmaceutical company that issues common stock listed on The Nasdaq Global Market to fund its operations and development activities. The company accesses public capital markets through shelf registration statements and at-the-market equity offering programs arranged with investment banks acting as sales agents.
Average Trading Volume: 2,467,356
Technical Sentiment Signal: Sell
Current Market Cap: $554.8M
See more insights into RCKT stock on TipRanks’ Stock Analysis page.